


DPH

Cat. No.:	HY-12070		
CAS No.:	484049-04-9		
Molecular Formula:	C ₁₈ H ₁₃ FN ₄ O ₂		
Molecular Weight:	336.32		
Target:	Bcr-Abl		
Pathway:	Protein Tyrosine Kinase/RTK		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (297.34 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		2.9734 mL	14.8668 mL	29.7336 mL
		5 mM		0.5947 mL	2.9734 mL	5.9467 mL
10 mM			0.2973 mL	1.4867 mL	2.9734 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.43 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	DPH is a potent cell permeable c-Abl activator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation.
In Vitro	DPH binds to the myristoyl binding site and prevents the formation of the bent conformation of the αI helix through steric hindrance, a mode of action distinct from the previously identified allosteric c-Abl inhibitor, GNF-2, that also binds to the myristoyl binding site. DPH represents the first cell-permeable, small-molecule tool compound for c-Abl activation ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Toxicol Sci. 2018 Sep 1;165(1):232-243.
- Mol Cell Neurosci. 2017 Dec;85:226-234.
- SSRN. 2021 Feb 18.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Yang J, et al. Discovery and characterization of a cell-permeable, small-molecule c-Abl kinase activator that binds to the myristoyl binding site. Chem Biol. 2011 Feb 25;18(2):177-86
- [2]. Shapiro LP, et al. Corticosteroid-induced dendrite loss and behavioral deficiencies can be blocked by activation of Abl2/Arg kinase. Mol Cell Neurosci. 2017 Oct 26;85:226-234.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA